MCID: VSC007
MIFTS: 64

Vascular Disease

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Vascular Disease

MalaCards integrated aliases for Vascular Disease:

Name: Vascular Disease 11 14 16 75
Vascular Diseases 53 41 43 14 71
Aneurysm 43 63 16 71
Spinal Cord Ischemia 43 16 71
Spinal Cord Vascular Diseases 43 71
Vascular Tissue Disease 11
Vascular Anomaly 53

Classifications:



External Ids:

Disease Ontology 11 DOID:178
ICD9CM 34 442.9
ICD10 31 I72.9
UMLS 71 C0002940 C0042373 C0752127 more

Summaries for Vascular Disease

MedlinePlus: 41 What are vascular diseases? Your vascular system is your body's network of blood vessels. It includes your: Arteries, which carry oxygen-rich blood from your heart to your tissues and organs Veins, which carry the blood and waste products back to your heart Capillaries, which are tiny blood vessels that connect your small arteries to your small veins. The walls of the capillaries are thin and leaky, to allow for an exchange of materials between your tissues and blood. Vascular diseases are conditions which affect your vascular system. They are common and can be serious. Some types include: Aneurysm - a bulge or "ballooning" in the wall of an artery Atherosclerosis - a disease in which plaque builds up inside your arteries. Plaque is made up of fat, cholesterol, calcium, and other substances found in the blood. Blood clots, including deep vein thrombosis and pulmonary embolism Coronary artery disease and carotid artery disease, diseases that involve the narrowing or blockage of an artery. The cause is usually a buildup of plaque. Raynaud's disease - a disorder that causes the blood vessels to narrow when you are cold or feeling stressed Stroke - a serious condition that happens when blood flow to your brain stops. Varicose veins - swollen, twisted veins that you can see just under the skin Vasculitis - inflammation of the blood vessels What causes vascular diseases? The causes of vascular diseases depend on the specific disease. These causes include: Genetics Heart diseases such as high cholesterol and high blood pressure Infection Injury Medicines, including hormones Sometimes the cause is unknown. Who is at risk for vascular diseases? The risk factors for vascular diseases can vary, depending on the specific disease. But some of the more common risk factors include: Age - your risk of some diseases goes up as you get older Conditions that can affect the heart and blood vessels, such as diabetes or high cholesterol Family history of vascular or heart diseases Infection or injury that damages your veins Lack of exercise Obesity Pregnancy Sitting or standing still for long periods of time Smoking What are the symptoms of vascular diseases? The symptoms for each disease are different. How are vascular diseases diagnosed? To make a diagnosis, your health care provider will do a physical exam and ask about your symptoms and medical history. You may have imaging tests and/or blood tests. How are vascular diseases treated? Which treatment you get depends on which vascular disease you have and how severe it is. Types of treatments for vascular diseases include: Lifestyle changes, such as eating a heart-healthy diet and getting more exercise Medicines, such as blood pressure medicines, blood thinners, cholesterol medicines, and clot-dissolving drugs. In some cases, providers use a catheter to send medicine directly to a blood vessel. Non-surgical procedures, such as angioplasty, stenting, and vein ablation Surgery Can vascular diseases be prevented? There are steps you can take to help prevent vascular diseases: Make healthy lifestyle changes, such as eating a heart-healthy diet and getting more exercise Don't smoke. If you are already a smoker, talk to your health care provider for help in finding the best way for you to quit. Keep your blood pressure and cholesterol in check If you have diabetes, control your blood sugar Try not to sit or stand for up long periods of time. If you do need to sit all day, get up and move around every hour or so. If you traveling on a long trip, you can also wear compression stockings and regularly stretch your legs.

MalaCards based summary: Vascular Disease, also known as vascular diseases, is related to peripheral vascular disease and heart aneurysm, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Vascular Disease is MIR145 (MicroRNA 145), and among its related pathways/superpathways are Signaling by Receptor Tyrosine Kinases and Cell differentiation - expanded index. The drugs Eplerenone and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, heart and endothelial, and related phenotypes are homeostasis/metabolism and cardiovascular system

PubMed Health : 63 Aneurysm: An aneurysm (AN-u-rism) is a balloon-like bulge in an artery. Arteries are blood vessels that carry oxygen-rich blood to your body. Arteries have thick walls to withstand normal blood pressure. However, certain medical problems, genetic conditions, and trauma can damage or injure artery walls. The force of blood pushing against the weakened or injured walls can cause an aneurysm. An aneurysm can grow large and rupture (burst) or dissect. A rupture causes dangerous bleeding inside the body. A dissection is a split in one or more layers of the artery wall. The split causes bleeding into and along the layers of the artery wall. Both rupture and dissection often are fatal.

Disease Ontology: 11 A cardiovascular system disease that primarily affects the blood vessels which includes the arteries, veins and capillaries that carry blood to and from the heart.

Wikipedia: 75 Vascular disease is a class of diseases of the blood vessels - the arteries and veins of the circulatory... more...

Related Diseases for Vascular Disease

Diseases in the Vascular Disease family:

Rare Vascular Disease

Diseases related to Vascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2692)
# Related Disease Score Top Affiliating Genes
1 peripheral vascular disease 33.8 VEGFA SERPINE1 NOS3 MTHFR INS CRP
2 heart aneurysm 33.2 MMP9 CRP ACE
3 coronary aneurysm 33.1 MMP9 CRP ACE
4 buerger disease 33.1 VEGFA NOS3 CRP
5 hepatic vascular disease 33.0 VEGFA SERPINE1 NOS3 MIR214 INS CRP
6 retinal vascular disease 32.8 VEGFA NOS3 MIR21 INS ACE
7 arteriosclerosis 32.8 SERPINE1 MMP9 MIR21 INS ELN CRP
8 renal artery disease 32.8 NOS3 INS CRP ACE
9 polycystic kidney disease 32.5 VEGFA MAPK1 INS CRP ACE
10 thrombosis 32.5 SERPINE1 NOS3 MTHFR CBS
11 vein disease 32.4 VEGFA SERPINE1 MTHFR MMP9 INS CRP
12 diabetic angiopathy 32.4 VEGFA NOS3 INS APOE
13 aphasia 32.3 CRP CBS APOE
14 hypertension, essential 32.2 VEGFA SERPINE1 NOS3 MTHFR MMP9 MIR214
15 cerebrovascular disease 32.2 MTHFR MIR21 MIR146A MIR145 MIR143 MIR125A
16 ischemia 32.2 VEGFA NOS3 MIR21 MIR146A ACE
17 aortic aneurysm, familial thoracic 1 32.1 VEGFA SERPINE1 NOS3 MMP9 MIR21 MIR145
18 intermittent claudication 32.1 VEGFA SERPINE1 CRP ACE
19 atherosclerosis susceptibility 32.1 SERPINE1 NOS3 MTHFR MMP9 INS ELN
20 tinea unguium 32.1 CRP CBS
21 pulmonary hypertension 32.0 VEGFA SERPINE1 NOS3 MIR21 ELN CRP
22 mitral valve insufficiency 32.0 ELN CRP ACE
23 peripheral artery disease 32.0 VEGFA NOS3 MIR21 INS CRP APOE
24 cholesterol embolism 32.0 CRP ACE
25 stroke, ischemic 32.0 VEGFA SERPINE1 NOS3 MTHFR MMP9 MIR21
26 hypercholesterolemia, familial, 1 31.9 NOS3 INS CRP APOE APOB ACE
27 hyperhomocysteinemia 31.9 SERPINE1 NOS3 MTHFR CRP CBS APOE
28 aortic aneurysm, familial abdominal, 1 31.9 VEGFA SERPINE1 NOS3 MMP9 MIR21 ELN
29 coronary heart disease 1 31.9 SERPINE1 INS CRP APOE APOB ACE
30 lipid metabolism disorder 31.9 SERPINE1 NOS3 MIR21 INS CRP CBS
31 aortic aneurysm 31.9 VEGFA SERPINE1 NOS3 MMP9 MIR21 MIR145
32 carotid stenosis 31.9 VEGFA NOS3 MTHFR MMP9 CRP APOE
33 type 1 diabetes mellitus 31.9 VEGFA MTHFR INS APOE APOB ACE
34 arteries, anomalies of 31.9 VEGFA NOS3 MIR214 MIR21 MIR146A MIR145
35 kidney disease 31.8 VEGFA SERPINE1 NOS3 MTHFR MIR21 MAPK1
36 transient cerebral ischemia 31.8 MTHFR INS CRP APOE ACE
37 vascular dementia 31.8 VEGFA MTHFR INS CBS APOE ACE
38 angina pectoris 31.7 NOS3 INS CRP ACE
39 chronic kidney disease 31.7 NOS3 MTHFR MIR21 INS CRP APOB
40 pericardial effusion 31.7 VEGFA CRP ACE
41 limb ischemia 31.7 VEGFA NOS3 MIR21 CRP ACE
42 thrombophilia due to thrombin defect 31.7 SERPINE1 MTHFR CBS
43 microvascular complications of diabetes 5 31.7 VEGFA SERPINE1 NOS3 MIR21 INS ACE
44 systemic scleroderma 31.7 VEGFA MIR21 CRP ACE
45 diabetes mellitus 31.7 VEGFA SERPINE1 NOS3 MTHFR MMP9 MIR21
46 carotid artery disease 31.7 MMP9 INS CRP APOE APOB ACE
47 abdominal obesity-metabolic syndrome 1 31.6 SERPINE1 INS APOB
48 familial hyperlipidemia 31.6 SERPINE1 INS CRP APOE APOB ACE
49 heart disease 31.6 VEGFA SERPINE1 NOS3 MTHFR MMP9 MIR214
50 microvascular complications of diabetes 1 31.5 VEGFA MMP9 INS

Graphical network of the top 20 diseases related to Vascular Disease:



Diseases related to Vascular Disease

Symptoms & Phenotypes for Vascular Disease

UMLS symptoms related to Vascular Disease:


angina pectoris; chest pain; edema; flushing; leg cramps; warm skin; vein pain

MGI Mouse Phenotypes related to Vascular Disease:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 ACE APOB APOE CBS CRP CYBB
2 cardiovascular system MP:0005385 10.34 ACE APOB APOE CBS CRP CYBB
3 muscle MP:0005369 10.31 APOB APOE CBS CYBB ELN INS
4 immune system MP:0005387 10.25 ACE APOB APOE CBS CRP CYBB
5 liver/biliary system MP:0005370 10.18 ACE APOB APOE CBS INS MAPK1
6 renal/urinary system MP:0005367 10.16 ACE APOE CBS CYBB INS MMP9
7 neoplasm MP:0002006 10.07 ACE CYBB MAPK1 MIR146A MMP9 SERPINE1
8 skeleton MP:0005390 10.06 APOE CBS ELN INS MAPK1 MIR146A
9 respiratory system MP:0005388 9.97 APOE CBS ELN MAPK1 MMP9 NOS3
10 vision/eye MP:0005391 9.96 APOB APOE CBS INS MAPK1 MIR146A
11 hematopoietic system MP:0005397 9.93 ACE APOE CBS CYBB INS MAPK1
12 mortality/aging MP:0010768 9.83 ACE APOB APOE CBS CYBB ELN
13 integument MP:0010771 9.28 APOE CBS INS MAPK1 MIR146A MMP9

Drugs & Therapeutics for Vascular Disease

PubMed Health treatment related to Vascular Disease: 63

Aortic aneurysms are treated with medicines and surgery . Small aneurysms that are found early and aren’t causing symptoms may not need treatment . Other aneurysms need to be treated. The goals of treatment may include: Preventing the aneurysm from growing Preventing or reversing damage to other body structures Preventing or treating a rupture or dissection Allowing you to continue doing your normal daily activities Treatment for an aortic aneurysm is based on its size. Your doctor may recommend routine testing to make sure an aneurysm isn't getting bigger. This method usually is used for aneurysms that are smaller than 5 centimeters (about 2 inches) across. How often you need testing (for example, every few months or every year) is based on the size of the aneurysm and how fast it's growing. The larger it is and the faster it's growing, the more often you may need to be checked.

Drugs for Vascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 600)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Eplerenone Approved Phase 4 107724-20-9 443872
2
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
3
Acetazolamide Approved, Vet_approved Phase 4 59-66-5, 1424-27-7 1986
4
Acyclovir Approved Phase 4 59277-89-3 2022
5
Methyltestosterone Approved Phase 4 58-18-4 6010
6
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0 21873174 65157
7
Testosterone enanthate Approved Phase 4 315-37-7 9416
8
Testosterone Approved, Investigational Phase 4 58-22-0 5408 6013
9
Vorapaxar Approved Phase 4 618385-01-6 72455102 10077130
10
Nitric Oxide Approved Phase 4 10102-43-9 145068
11
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
12
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
13
Nadroparin Approved, Investigational Phase 4
14
Reviparin Approved, Investigational Phase 4 9041-08-1
15
Calcium acetate Approved, Investigational Phase 4 62-54-4
16
Sevelamer Approved Phase 4 52757-95-6 3085017
17
Iodine Approved, Investigational Phase 4 7553-56-2 807
18
Rosiglitazone Approved, Investigational Phase 4 122320-73-4, 155141-29-0 77999
19
Phylloquinone Approved, Investigational Phase 4 84-80-0 5284607
20
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
21
Cinacalcet Approved Phase 4 226256-56-0 156419
22
Aflibercept Approved Phase 4 862111-32-8 124490314
23
Simvastatin Approved Phase 4 79902-63-9 54454
24
Evolocumab Approved Phase 4 1256937-27-5
25
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
26
Allopurinol Approved Phase 4 315-30-0 2094 135401907
27
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959 6435378 5311181
28
Defibrotide Approved, Investigational Phase 4 83712-60-1
29
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
30
Sorbitol Approved, Investigational Phase 4 69-65-8, 50-70-4 453 6251 5780
31
Acenocoumarol Approved, Investigational Phase 4 152-72-7 54676537 9052
32
Phenprocoumon Approved, Investigational Phase 4 435-97-2 54680692 9908
33
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
34
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
35
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
36
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
37
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
38
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
39
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
40
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
41
Abacavir Approved, Investigational Phase 4 136470-78-5, 188062-50-2 441300
42
Zidovudine Approved Phase 4 30516-87-1 35370
43
Cobicistat Approved Phase 4 1004316-88-4 24950485 25151504
44
Rilpivirine Approved Phase 4 500287-72-9 6451164
45
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
46
Dolutegravir Approved Phase 4 1051375-16-6 57414794 54726191
47
Rivaroxaban Approved Phase 4 366789-02-8 9875401
48
Macitentan Approved Phase 4 441798-33-0 16004692
49
Ramipril Approved Phase 4 87333-19-5 5362129
50
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541

Interventional clinical trials:

(show top 50) (show all 2890)
# Name Status NCT ID Phase Drugs
1 The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions Unknown status NCT01952457 Phase 4
2 Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS) Unknown status NCT01083394 Phase 4
3 Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease Unknown status NCT00986752 Phase 4
4 The Study to Compare the Treatment of Stent and Prothesis Bypass in SFA Occlusions Unknown status NCT01147419 Phase 4
5 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part I) Unknown status NCT01171703 Phase 4
6 DCLI-II:Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part II) Unknown status NCT01173094 Phase 4
7 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
8 A Random, Open-label Multicenter, Phase IV Study Assessing the Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy Unknown status NCT04380974 Phase 4 Anti-VEGF drug
9 In.Pact Flexion, a Physician Initiated Trial Investigating the Performance of the In.Pact Admiral Drug-eluting Balloon for the Treatment of Popliteal Lesions Unknown status NCT02678065 Phase 4
10 Intraocular Cytokine Changes in Recurrence of Polypoidal Choroidal Vasculopathy Unknown status NCT02976194 Phase 4 ranibizumab
11 Evaluation of Closed Incision Negative Pressure Device (Prevena) to Prevent Vascular Wound Complications Unknown status NCT02581904 Phase 4
12 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA) Unknown status NCT02033135 Phase 4
13 Open-label, Non-randomized, Unmasked, Study of IAI in Patients Which Choroidal Neovascularization Secondary to Polypoidal Choroidal Vasculopathy (PCV) Unknown status NCT02092532 Phase 4 Rescue Intravitreal Aflibercept Injection
14 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Unknown status NCT02660866 Phase 4 Placebo + background APT + SMT;Vorapaxar 2.08 mg/d + background APT + SMT.
15 Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease (Evol-PAD) Unknown status NCT04306081 Phase 4 Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.
16 The Effects of Statin and Angiotensin-converting Enzyme Inhibitor on Coronary Flow Reserve, indEx of Microcirculatory Resistance, and Symptoms in Patients With Spontaneous Coronary Artery Dissection (SAFER-SCAD) Study Unknown status NCT02008786 Phase 4 ramipril;rosuvastatin;placebo
17 SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial Unknown status NCT02959606 Phase 4 Sarpogrelate SR 300mg;Clopidogrel
18 Multicenter Randomized Controlled Study of Intravitreal Ranibizumab and Triamcinolone Acetonide Combination Therapy Versus Ranibizumab Monotherapy in Patients With Polypoidal Choroidal Vasculopathy Unknown status NCT02806752 Phase 4 Triamcinolone Acetonide;Ranibizumab
19 Tailored Strategy for Residual Platelet Activity In Advanced Peripheral Artery Disease: New Optimal Management. Unknown status NCT01627431 Phase 4 Acetylsalicylic acid;Clopidogrel
20 The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV) Unknown status NCT03159884 Phase 4 Conbercept
21 Platelets Induced Vasodilation, in Vitro and in Vivo Study in Patients With Arteriopathy and Healthy Subjects. Unknown status NCT00152646 Phase 4 placebo, aspirine, clopidogrel
22 A Randomized Controlled Trial Comparing Usual Care With a Multifactorial Intensified Intervention on Cardiovascular Risk Factors in Subjects With Arterial Peripheral Disease With and Without Diabetes. The Taulí Intervention Program (TIP). Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
23 Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia and Mixed Vascular and Alzheimer's Dementia Unknown status NCT00229333 Phase 4 Escitalopram
24 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROLTM Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP-2 Trial) Unknown status NCT01653600 Phase 4
25 Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy Unknown status NCT03244657 Phase 4 conbercept ophthalmic injection (0.5mg)
26 The Effect of Ivabradine Treatment on Exercise Capacity in Patients With Cardiac Allograft Vasculopathy After Heart Transplantation Unknown status NCT03405831 Phase 4 Ivabradine;Placebo
27 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
28 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
29 Effect of Topical Anesthesia on Patient's Pain Discomfort and Radial Artery Spasm in Transradial Catheterization Unknown status NCT03501212 Phase 4 Topical Anesthetic;Placebo
30 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
31 Eplerenone in the Management of Abdominal Aortic Aneurysms: A Proof-Of-Concept Randomised Controlled Trial Unknown status NCT02345590 Phase 4 Eplerenone
32 The Effect of Immunonutrition on Outcome and Postoperative Recovery in Patients Undergoing Elective Surgical Repair of a Thoraco (Abdominal) Aneurysm Aorta Unknown status NCT00339053 Phase 4 Immunonutrition ( Impact)
33 Prophylactic Mesh Implantation After Abdominal Aortic Aneurysm Repair. A Prospective, Randomised, Controlled Study Unknown status NCT01353443 Phase 4
34 A Randomised Controlled Trial of the Effectiveness of Acetazolamide in Reducing Cerebrospinal Fluid Pressure for Patients Undergoing Thoracic-abdominal Aortic Repair Unknown status NCT01889498 Phase 4 Acetazolamide
35 Comparative Study of Covered Stent With Coil Embolization in the Treatment of Cranial Internal Carotid Artery Aneurysm: A Nonrandomized Prospective Trial Unknown status NCT01029938 Phase 4
36 Randomized Comparison of Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus a Common Antiplatelet Treatment for Intracranial Aneurysm Stent-assisted Coiling Unknown status NCT02224131 Phase 4 Aspirin and clopidogrel
37 Delayed Vasospasm After Aneurysm With the Standardization Treatment of Traditional Chinese Medicine Unknown status NCT01840761 Phase 4 herbal drug;placebo
38 Fast-track in Endovascular Aortic Aneurysm Repair With Desflurane and Sevoflurane: a Randomized Clinical Trial Unknown status NCT03917186 Phase 4 Sevoflurane;Desflurane
39 Pilot Study of of Renal Arterial Sympathetic Denervation by Cryotherapy During Open Surgery for Aortic Aneurysm Unknown status NCT02345603 Phase 4
40 Ultrasound Guided Erector Spinae Block Versus Ultrasound Guided Thoracic Paravertebral Block for Pain Relief in Patients With Acute Thoracic Herpes Zoster Unknown status NCT04656821 Phase 4 Control Rx
41 Randomized, Controlled, Prospective Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis Completed NCT00837954 Phase 4
42 A Prospective Randomized Controlled Efficacy and Safety Trial of the SafeSeal Hemostasis Patch Compared to Manual Compression for Achieving Vascular Hemostasis Following Percutaneous Coronary and Peripheral Intervention. Completed NCT00481741 Phase 4
43 ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg. Completed NCT00442325 Phase 4 Atorvastatin (Lipitor)
44 Physician Initiated Trial Investigating the Efficacy of the Implant of EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions Completed NCT00637741 Phase 4
45 Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication Completed NCT00822172 Phase 4 cilostazol
46 Effects of Cilostazol on Vascular Endothelial Growth Factor , Inflammatory and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease. Completed NCT00431249 Phase 4 Cilostazol
47 Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C & D Iliac Lesions Completed NCT00764777 Phase 4
48 Balloon Angioplasty vs. Primary Stenting of Femoropopliteal Arteries Using Self-Expandable Nitinol Stents - a Randomized Controlled Trial Completed NCT00715416 Phase 4
49 A Randomised, Double Blind, Placebo Controlled, Parallel Pilot Study to Test the Effect of Testosterone Treatment on Peripheral Vascular Disease in Hypogonadal Men With Type 2 Diabetes Mellitus Completed NCT00504712 Phase 4 Testosterone;saline
50 ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg Completed NCT00442845 Phase 4 Atorvastatin (Lipitor)

Search NIH Clinical Center for Vascular Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Baclofen

Cochrane evidence based reviews: vascular diseases

Genetic Tests for Vascular Disease

Anatomical Context for Vascular Disease

Organs/tissues related to Vascular Disease:

MalaCards : Spinal Cord, Heart, Endothelial, Bone Marrow, Brain, Smooth Muscle, Skin

Publications for Vascular Disease

Articles related to Vascular Disease:

(show top 50) (show all 71565)
# Title Authors PMID Year
1
MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. 62 46
19542014 2009
2
MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. 62 46
17478730 2007
3
ULTrasound-guided TRAnsfemoral puncture in COmplex Large bORe PCI: study protocol of the UltraCOLOR trial. 41
36456007 2022
4
The effect of haptoglobin genotype on the association of asymmetric dimethylarginine and DDAH 1 polymorphism with diabetic macroangiopathy. 41
36461077 2022
5
Hyperglycemic conditions induce rapid cell dysfunction-promoting transcriptional alterations in human aortic endothelial cells. 41
36463298 2022
6
Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. 53 62
20232317 2010
7
Migraine and coronary artery disease: an open study on the genetic polymorphism of the 5, 10 methylenetetrahydrofolate (MTHFR) and angiotensin I-converting enzyme (ACE) genes. 53 62
20518725 2010
8
EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting LOX-1-mediated signaling. 53 62
20203069 2010
9
Notch and transforming growth factor-beta (TGFbeta) signaling pathways cooperatively regulate vascular smooth muscle cell differentiation. 53 62
20368328 2010
10
Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. 53 62
20421882 2010
11
Microvascular complications are associated with low levels of maternal sE-selectin and sVCAM-1 in pregnancy complicated with pregestational diabetes mellitus. 53 62
20129688 2010
12
Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. 53 62
20466987 2010
13
Evidence for the efficacy of ARBs across the cardiovascular continuum. 53 62
20302552 2010
14
Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. 53 62
20079523 2010
15
Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. 53 62
20164116 2010
16
Weighting the potential of using tenascin C in diagnosis and therapy of atherosclerosis. 53 62
20513936 2010
17
Genetic variants promoting smooth muscle cell proliferation can result in diffuse and diverse vascular diseases: evidence for a hyperplastic vasculomyopathy. 53 62
20130469 2010
18
Vascular oxidative stress: the common link in hypertensive and diabetic vascular disease. 53 62
20422735 2010
19
Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. 53 62
20110448 2010
20
APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome. 53 62
19878946 2010
21
Upregulation of heme oxygenase-1 inhibits the maturation and mineralization of osteoblasts. 53 62
20020468 2010
22
High glucose and elevated fatty acids suppress signaling by the endothelium protective ligand angiopoietin-1. 53 62
20079751 2010
23
Visfatin, glucose metabolism and vascular disease: a review of evidence. 53 62
20346149 2010
24
JNK-ATF-2 inhibits thrombomodulin (TM) expression by recruiting histone deacetylase4 (HDAC4) and forming a transcriptional repression complex in the TM promoter. 53 62
20116378 2010
25
A novel murine elastase saccular aneurysm model for studying bone marrow progenitor-derived cell-mediated processes in aneurysm formation. 53 62
20173550 2010
26
Cathepsin K gene disruption does not affect murine aneurysm formation. 53 62
19775691 2010
27
The association between the -374T/A polymorphism of the receptor for advanced glycation endproducts gene and blood pressure and arterial stiffness is modified by glucose metabolism status: the Hoorn and CoDAM studies. 53 62
20051912 2010
28
Endothelial nitric oxide synthase and nicotinamide adenosine dinucleotide phosphate oxidase p22phox gene (C242T) polymorphisms and systemic lupus erythematosus in a Chinese Population. 53 62
19965945 2010
29
TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. 53 62
20101093 2010
30
Fibulin-4 deficiency results in ascending aortic aneurysms: a potential link between abnormal smooth muscle cell phenotype and aneurysm progression. 53 62
20019329 2010
31
An overview of the Guangzhou biobank cohort study-cardiovascular disease subcohort (GBCS-CVD): a platform for multidisciplinary collaboration. 53 62
19587700 2010
32
Haptoglobin phenotype correlates with the extent of cerebral deep white matter lesions in hypertensive patients. 53 62
20158468 2010
33
The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression. 53 62
20056946 2010
34
Matrix metalloproteinases in vascular disease--a potential therapeutic target? 53 62
19485936 2010
35
Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. 53 62
20204740 2010
36
The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. 53 62
20034371 2010
37
Paraoxonase 1 status as a risk factor for disease or exposure. 53 62
20221868 2010
38
Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients. 53 62
20185929 2010
39
C-reactive protein gene variant and the human left ventricular growth response to exercise: data from The LARGE Heart Study. 53 62
19834334 2010
40
Plasma homocysteine, apolipoprotein E status and vascular disease in elderly patients with mental illness. 53 62
19943806 2010
41
The protective role of adiponectin in pulmonary vascular disease. 53 62
19880503 2010
42
Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum. 53 62
19916212 2009
43
Homocysteine promotes vascular smooth muscle cell migration by induction of the adipokine resistin. 53 62
19828833 2009
44
Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation. 53 62
19846878 2009
45
Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites. 53 62
19423112 2009
46
Investigation of SERPINE1 genetic polymorphism in Macedonian patients with occlusive artery disease and deep vein thrombosis. 53 62
20017074 2009
47
Coordinated regulation of angiopoietin-1 and vascular endothelial growth factor by arsenite in human brain microvascular pericytes: implications of arsenite-induced vascular dysfunction. 53 62
19622383 2009
48
Distribution of endothelial nitric oxide synthase gene polymorphisms in Turkish population. 53 62
19730129 2009
49
Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress. 53 62
19360379 2009
50
Aneurysm formation and bradykinin. 53 62
19707733 2009

Variations for Vascular Disease

Expression for Vascular Disease

Search GEO for disease gene expression data for Vascular Disease.

Pathways for Vascular Disease

Pathways related to Vascular Disease according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1 12.22 VEGFA NOS3 MMP9 MAPK1 INS CYBB
2
Show member pathways
11.63 MIR214 MIR145 MIR143
3
Show member pathways
11.61 SERPINE1 NOS3 MAPK1 ACE
4 11.6 VEGFA MMP9 ELN
5 11.51 MIR21 MIR145 MIR143
6
Show member pathways
11.47 VEGFA MMP9 MAPK1
7 11.39 VEGFA NOS3 MAPK1
8 11.36 VEGFA MMP9 MAPK1
9 11.29 MIR146A MIR21 MIR214
10 11.18 VEGFA MMP9 MAPK1
11 11.05 MMP9 APOE ACE
12
Show member pathways
10.97 VEGFA MAPK1 CRP
13 10.69 MMP9 MAPK1
14 10.61 NOS3 MMP9 MAPK1
15 10.6 VEGFA MIR145 MIR143 MAPK1
16 10.57 VEGFA NOS3
17 10.49 MTHFR CBS
18 10.48 MIR146A APOE

GO Terms for Vascular Disease

Cellular components related to Vascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 10.03 MIR214 MIR21 MIR146A MIR145 MIR143 MIR125A
2 extracellular space GO:0005615 9.62 VEGFA SERPINE1 MMP9 MIR21 MIR146A MIR143
3 intermediate-density lipoprotein particle GO:0034363 9.46 APOE APOB
4 extracellular vesicle GO:1903561 9.35 APOE MIR125A MIR21 MIR214

Biological processes related to Vascular Disease according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 vasodilation GO:0042311 10.1 NOS3 INS APOE
2 blood vessel remodeling GO:0001974 10.09 ACE CBS NOS3
3 cellular response to cadmium ion GO:0071276 10.08 CYBB MAPK1 MMP9
4 positive regulation of blood vessel endothelial cell migration GO:0043536 10.04 VEGFA NOS3 MIR143
5 blood vessel diameter maintenance GO:0097746 10.03 NOS3 CBS ACE
6 positive regulation of gene expression GO:0010628 10.03 VEGFA NOS3 MIR21 MIR146A MIR125A MAPK1
7 positive regulation of protein kinase B signaling GO:0051897 10.02 VEGFA MIR21 MIR143 INS
8 artery morphogenesis GO:0048844 10 VEGFA APOE APOB
9 positive regulation of angiogenesis GO:0045766 9.96 CYBB MIR143 MIR21 NOS3 SERPINE1 VEGFA
10 cellular response to hypoxia GO:0071456 9.95 VEGFA MIR214 MIR146A CYBB CBS
11 lipoprotein biosynthetic process GO:0042158 9.94 APOE APOB
12 lipoprotein catabolic process GO:0042159 9.93 APOE APOB
13 negative regulation of endothelial cell proliferation GO:0001937 9.9 MIR21 MIR146A APOE
14 positive regulation of dendritic spine maintenance GO:1902952 9.88 INS APOE
15 regulation of nitric oxide mediated signal transduction GO:0010749 9.88 CBS VEGFA
16 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.87 ACE VEGFA
17 activation of protein kinase B activity GO:0032148 9.85 MIR21 MIR143 INS
18 negative regulation of smooth muscle cell proliferation GO:0048662 9.8 NOS3 MIR145 MIR143 APOE
19 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.78 VEGFA MIR21 MIR146A
20 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.77 MMP9 MIR214 MIR21 MIR146A
21 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.67 MIR21 MIR146A MIR143
22 aorta smooth muscle tissue morphogenesis GO:0060414 9.63 MIR145 MIR143
23 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.59 MIR146A MIR125A
24 regulation of phenotypic switching GO:1900239 9.54 MIR145 MIR143
25 positive regulation of cellular response to hypoxia GO:1900039 9.51 MIR145 MIR21
26 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.46 MIR145 MIR143
27 negative regulation of interleukin-16 production GO:0032699 9.43 MIR145 MIR125A
28 negative regulation of angiogenesis GO:0016525 9.43 MIR214 MIR21 MIR146A MIR145 MIR143 MIR125A
29 negative regulation of gene expression GO:0010629 9.4 VEGFA MIR214 MIR21 MIR146A MIR125A INS

Molecular functions related to Vascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 low-density lipoprotein particle receptor binding GO:0050750 9.63 CRP APOE APOB
2 mRNA 3'-UTR binding GO:0003730 9.43 MIR214 MIR21 MIR146A MIR145 MIR143 MIR125A
3 mRNA base-pairing translational repressor activity GO:1903231 9.1 MIR214 MIR21 MIR146A MIR145 MIR143 MIR125A

Sources for Vascular Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....